Cate

Malaria: A parasitic disease caused by protozoan parasites from the Plasmodium genus. - Most deadly species: Plasmodium falciparum - Most widespread species: Plasmodium vivax
Global Impact: - Approximately 240 million cases annually. - Around 600,000 deaths each year. - 95% of deaths occur in Sub-Saharan Africa. - Most vulnerable population: Children under the age of 5, a leading cause of death in endemic regions.

Transmitted through bites from infected female mosquitoes (Anopheles).
Only female mosquitoes transmit malaria because they require blood meals for egg development.
Transmission peaks during tropical rainy seasons.

Malaria's life cycle is complex, making it difficult to control. - Stage 1: Infected female mosquito takes a blood meal, injecting approximately 100 sporozoites into the bloodstream. - Stage 2: Sporozoites reach the liver within approximately 30 minutes and replicate without noticeable symptoms for 7-14 days. - Stage 3: Released into the bloodstream as merozoites, infecting red blood cells, leading to clinical symptoms. - Stage 4: Some merozoites develop into gametocytes, the sexual form of the parasite. - Stage 5: Another mosquito bites the infected individual, ingesting gametocytes and continuing the cycle.

Based on WHO data (2024-2026): - 265 million cases and 608,000 deaths annually. - Major deaths in children under five: approximately 462,000. - 76% of malaria deaths occur in this age group.
Geographically concentrated: - Africa: 95% of cases (approximately 253 million). - Other regions affected include Southeast Asia (2%), Eastern Mediterranean (1.5%), Western Pacific (1%).
Trends: - Cases stabilized in endemic regions, with an increase from 233 million in 2019 to 249 million in 2022. - 5% reduction in deaths and a small decrease in child mortality.

Life cycle complexity complicates treatment and vaccine development.
Plasmodium has a large genome (>5,000 genes) that can change surface proteins, evading immune detection.
Difficulties in laboratory growth, lack of animal models, and need for strong adjuvants complicate vaccine stability in tropical regions.
Timing issues: a 30-minute window between mosquito bite and liver infection.
Individuals don’t develop strong long-term immunity naturally, and repeated exposures may weaken immune responses.

1950s-60s: Focus on vector control (spraying to reduce mosquito populations).
1970s-80s: Introduction of insecticide-treated bed nets (ITNs).
1990s: Emphasis on chemoprevention including artemisinin-based combination therapies (ACTs) and seasonal malaria chemoprevention.
Vaccine Development: Ongoing since 1987, leading to the Mosquirix vaccine rollout in 2021.

Developed by GlaxoSmithKline in partnership with the PATH Malaria Vaccine Initiative and Walter Reed Army Institute of Research.
First malaria vaccine and the first vaccine against any human parasite.
Efficacy: Approximately 30% against clinical malaria.
Requires a 4-dose schedule beginning at 5 months of age.
Pilot programs began in 2022 in Ghana, Kenya, and Malawi with plans expanding across 20 African countries.
Initial findings show a 13% reduction in all-cause child mortality and significant reductions in severe malaria hospitalizations.
Type: Recombinant protein vaccine fusing Plasmodium falciparum circumsporozoite protein with the hepatitis B surface antigen.

Components of the Vaccine: - r (repeat region): Contains NANP repeats essential for sporozoite stage recognition. - T (T cell epitopes): Stimulate cellular immunity to aid in destroying infected cells. - S (hepatitis B surface antigen): Acts as a carrier, enhancing vaccine efficacy by forming virus-like particles.

The CSP serves as a primary target; it forms a dense coat over the sporozoites.
The N-terminal domain assists in sporozoite motility; the C-terminal adds structural integrity.
Key immunological target regions help neutralize sporozoites before they infect the liver.

Composition: Liposomal MPL and QS-21, amplifying immune signals by a tenfold increase of antibody production.
Crucial in resource-limited settings for sustaining long-lasting immunity.

Vaccine administered as an intramuscular injection (0.5 ml per dose).
Dendritic cells recognize CSP antigen and activate the immune system.
B cells produce anti-CSP IgG antibodies, reaching peak levels 3-4 weeks post-vaccination.
Protective antibodies are critical during the 30-minute window before the parasite reaches the liver.
T-cell responses are mediated mainly by CD4+ and CD8+ T cells.

Safety Profile: Generally favorable; mild side effects such as injection site pain and fevers; rare febrile seizures noted.
Trial Overview: Phase 3 trials (2011-2014) demonstrated a 36% reduction in clinical malaria cases and a 39% reduction in severe cases post-first three doses.
Completing all four doses increases protection to 42% against severe malaria.

Requires cold chain storage (2-8 °C) and costs approximately $5-$10 per child.
Complex scheduling may lead to high dropout rates, especially in rural areas.
While moderate in efficacy, further development of new vaccines holds potential for better efficiency against malaria.

ITNs: Reduce exposure to infectious mosquito bites by 15-90%.
Indoor Residual Spraying (IRS): Kills resting mosquitoes.
Combined Effect: ITNs + vaccine reduces malaria incidence by about 60%; IRS + vaccine by 55%. Seasonal chemoprevention can increase overall efficacy by 70%.

First vaccine against a human parasite, potentially paving the way for future vaccines.
Brings attention to investment in parasite vaccinology and new platforms.
Promotes public health equity by targeting diseases affecting underserved populations and building trust.
Addresses climate change implications through adaptive intervention strategies.

Next Generation Vaccine: R21 vaccine, developed by the University of Oxford with higher efficacy (around 75%).
Easily manufactured at scale; uses different adjuvant (Matrix-M) for stronger immune response.
mRNA vaccines are also in the pipeline, targeted to potentially simplify production and effectiveness in targeting multiple antigens.
R21 has already seen approval in over 20 countries with ambitious production plans for 2026.

Mosquirix demonstrates potential in malaria prevention, lays the groundwork for future vaccine strategies, and highlights the importance of comprehensive public health approaches.
Continued investment and integration with existing measures are essential for combating malaria effectively.